- Record: found
- Abstract: found
- Article: not found
A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy.
Read this article at
ScienceOpenPubMed
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC).